重组Anti-IL-6抗体[EPR21711] (ab233706)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR21711] to IL-6
- Suitable for: Flow Cyt (Intra), WB, ICC/IF, IP
- Knockout validated
- Reacts with: Human
Related conjugates and formulations
概述
-
产品名称
Anti-IL-6抗体[EPR21711]
参阅全部 IL-6 一抗 -
描述
兔单克隆抗体[EPR21711] to IL-6 -
宿主
Rabbit -
经测试应用
适用于: Flow Cyt (Intra), WB, ICC/IF, IPmore details -
种属反应性
与反应: Human -
免疫原
Recombinant fragment. This information is proprietary to Abcam and/or its suppliers.
-
阳性对照
-
常规说明
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
性能
-
形式
Liquid -
存放说明
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
存储溶液
pH: 7.2
Preservative: 0.01% Sodium azide
Constituents: PBS, 40% Glycerol, 0.05% BSA -
Concentration information loading...
-
纯度
Protein A purified -
克隆
单克隆 -
克隆编号
EPR21711 -
同种型
IgG -
研究领域
相关产品
-
Alternative Versions
-
Conjugation kits
-
Isotype control
-
KO cell lines
-
KO cell lysates
-
Recombinant Protein
-
Related Products
应用
The Abpromise guarantee
Abpromise™承诺保证使用ab233706于以下的经测试应用
“应用说明”部分 下显示的仅为推荐的起始稀释度;实际最佳的稀释度/浓度应由使用者检定。
应用 | Ab评论 | 说明 |
---|---|---|
Flow Cyt (Intra) |
1/500.
|
|
WB |
1/1000. Detects a band of approximately 21 kDa (predicted molecular weight: 23 kDa).
|
|
ICC/IF |
1/50.
|
|
IP |
1/30.
|
说明 |
---|
Flow Cyt (Intra)
1/500. |
WB
1/1000. Detects a band of approximately 21 kDa (predicted molecular weight: 23 kDa). |
ICC/IF
1/50. |
IP
1/30. |
靶标
-
功能
Cytokine with a wide variety of biological functions. It is a potent inducer of the acute phase response. Plays an essential role in the final differentiation of B-cells into Ig-secreting cells Involved in lymphocyte and monocyte differentiation. It induces myeloma and plasmacytoma growth and induces nerve cells differentiation Acts on B-cells, T-cells, hepatocytes, hematopoeitic progenitor cells and cells of the CNS. Also acts as a myokine. It is discharged into the bloodstream after muscle contraction and acts to increase the breakdown of fats and to improve insulin resistance. -
疾病相关
Genetic variations in IL6 are associated with susceptibility to rheumatoid arthritis systemic juvenile (RASJ) [MIM:604302]. An inflammatory articular disorder with systemic-onset beginning before the age of 16. It represents a subgroup of juvenile arthritis associated with severe extraarticular features and occasionally fatal complications. During active phases of the disorder, patients display a typical daily spiking fever, an evanescent macular rash, lymphadenopathy, hepatosplenomegaly, serositis, myalgia and arthritis.
Note=A IL6 promoter polymorphism is associated with a lifetime risk of development of Kaposi sarcoma in HIV-infected men. -
序列相似性
Belongs to the IL-6 superfamily. -
翻译后修饰
N- and O-glycosylated. -
细胞定位
Secreted. - Information by UniProt
-
数据库链接
- Entrez Gene: 3569 Human
- Omim: 147620 Human
- SwissProt: P05231 Human
- Unigene: 654458 Human
-
别名
- Interleukin BSF 2 antibody
- B cell differentiation factor antibody
- B cell stimulatory factor 2 antibody
see all
图片
-
All lanes : Anti-IL-6 antibody [EPR21711] (ab233706) at 1/1000 dilution
Lane 1 : Wild-type A549 Brefeldin A (ab120299)-treated (5ug/ml, 4h) cell lysate
Lane 2 : Wild-type A549 IL-1ß (ab259387) (20 ng/ml, 24h) and Brefeldin A (ab120299)-treated (5 ug/ml for the last 4h) cell lysate
Lane 3 : IL-6 knockout A549 Brefeldin A (ab120299)-treated (5ug/ml, 4h) cell lysate
Lane 4 : IL-6 knockout A549 IL-1ß (ab259387) (20 ng/ml, 24h) and Brefeldin A (ab120299)-treated (5 ug/ml for the last 4h) cell lysate
Lysates/proteins at 30 µg per lane.
Performed under reducing conditions.
Predicted band size: 23 kDa
Observed band size: 25 kDa why is the actual band size different from the predicted?
Additional bands at: 40 kDa (possible non-specific binding)Lanes 1 - 4: Merged signal (red and green). Green - ab233706 observed at 25 kDa. Red - loading control ab7291 (Mouse anti-Alpha Tubulin [DM1A] observed at 55kDa.
ab233706 was shown to react with IL-6 in wild-type A549 cells in western blot with loss of signal observed in IL-6 knockout cell line ab273751 (knockout cell lysate ab275501). Wild-type and IL-6 knockout A549 cell lysates were subjected to SDS-PAGE. Membranes were blocked in fluorescent western blot (TBS-based) blocking solution before incubation with ab233706 and ab7291 (Mouse anti-Alpha Tubulin [DM1A] overnight at 4°C at a 1 in 1000 Dilution and a 1 in 20000 dilution respectively. Blots were incubated with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.
-
Immunofluorescent analysis of 4% paraformaldehyde-fixed, 0.1% Triton X-100 permeabilized HUVEC (human umbilical vein endothelial cell line) cells labeling IL6 with ab233706 at 1/50 dilution, followed by Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (ab150077) secondary antibody at 1/1000 dilution (green). Confocal image showing cytoplasmic staining in HUVEC cells treated with lipopolysaccharide (0.5 μg/ml) for 24h and Brefeldin A (300 ng/ml) for 20h. The nuclear counterstain is DAPI (blue). Tubulin is detected with Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker (Alexa Fluor® 594) (ab195889) at 1/200 dilution (red).
Secondary antibody only control: Used PBS instead of primary antibody, secondary antibody is Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (ab150077) secondary antibody at 1/1000 dilution.
-
Intracellular flow cytometric analysis of 4% paraformaldehyde-fixed, 90% methanol-permeabilized HUVEC (human umbilical vein endothelial cell line) treated with lipopolysaccharide (0.5 µg/ml) for 24h and Brefeldin A (300 ng/ml) for 20h (red) / untreated control (green) cells labeling IL6 with ab233706 at 1/500 compared with a Rabbit monoclonal IgG (ab172730) (black) and an unlabeled control (cells without incubation with primary antibody and secondary antibody) (blue). Goat anti rabbit IgG (Alexa Fluor® 488, ab150077), at 1/2000 dilution was used as the secondary antibody.
-
IL6 was immunoprecipitated from 0.35 mg HUVEC (human umbilical vein endothelial cell line) treated with lipopolysaccharide (0.5 µg/ml) for 24h and Brefeldin A (300 ng/ml) for 20h, whole cell lysate with ab233706 at 1/30 dilution. Western blot was performed from the immunoprecipitate using ab233706 at 1/1000 dilution. VeriBlot for IP Detection Reagent (HRP) (ab131366), was used for detection at 1/10000 dilution.
Lane 1: HUVEC treated with lipopolysaccharide (0.5 µg/ml) for 24h and Brefeldin A (300 ng/ml) for 20h, whole cell lysate 10 µg (Input).
Lane 2: ab233706 IP in HUVEC treated with lipopolysaccharide (0.5 µg/ml) for 24h and Brefeldin A (300 ng/ml) for 20h, whole cell lysate.
Lane 3: Rabbit monoclonal IgG (ab172730) instead of ab233706 in HUVEC treated with lipopolysaccharide (0.5 µg/ml) for 24h and Brefeldin A (300 ng/ml) for 20h, whole cell lysate.Blocking and dilution buffer and concentration: 5% NFDM/TBST.
Exposure time: 5 seconds. -
All lanes : Anti-IL-6 antibody [EPR21711] (ab233706) at 1/1000 dilution
Lane 1 : Untreated HUVEC (human umbilical vein endothelial cell line) whole cell lysate
Lane 2 : HUVEC treated with 0.5 µg/ml lipopolysaccharides (LPS) for 24 hours, added 300 ng/ml BFA last 20 hours, whole cell lysate
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/100000 dilution
Developed using the ECL technique.
Predicted band size: 23 kDa
Observed band size: 21 kDa why is the actual band size different from the predicted?
Exposure time: 3 minutesBlocking/ Dilution buffer and concentration: 5% NFDM/TBST.
The molecular mass observed is consistent with what has been described in the literature (PMID: 2523818, PMID: 2783321).
实验方案
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
数据表及文件
-
SDS download
-
Datasheet download
Certificate of Compliance
文献 (41)
ab233706 被引用在 41 文献中.
- Liu D et al. Ultrasound-triggered piezocatalytic composite hydrogels for promoting bacterial-infected wound healing. Bioact Mater 24:96-111 (2023). PubMed: 36582346
- Wu K & Wang L Stomatin-knockdown effectively attenuates sepsis-induced oxidative stress and inflammation of alveolar epithelial cells by regulating CD36. Exp Ther Med 23:69 (2022). PubMed: 34934440
- Shen J et al. Homeodomain-containing gene 10 contributed to breast cancer malignant behaviors by activating Interleukin-6/Janus kinase 2/Signal transducer and activator of transcription 3 pathway. Bioengineered 13:1335-1345 (2022). PubMed: 34983296
- Huang X et al. Urolithin B, a Gut Microbiota Metabolite, Reduced Susceptibility to Myocardial Arrhythmic Predisposition after Hypoxia. Dis Markers 2022:6517266 (2022). PubMed: 35178131
- Chen R et al. CID16020046, a GPR55 antagonist, attenuates sepsis‑induced acute kidney injury. Mol Med Rep 25:N/A (2022). PubMed: 35244189